Nov 5, 7:37 AM ET
Alnylam's board authorized a program to repurchase up to $1.0 billion of its common stock on November 2, 2026. The company also said Executive Vice President and Chief Commercialization Officer Tolga Tanguler will leave in December 2026, with a separation agreement still to be signed.
- Board authorized a repurchase program of up to $1.0 billion of common stock on November 2, 2026.
- The company anticipates repurchasing about $500 million by the end of 2026 and the balance during 2027.
- The program has no expiration date and does not obligate the company to buy any particular amount; it may be modified, suspended or discontinued at any time.
- Tolga Tanguler, Executive Vice President and Chief Commercialization Officer, will depart in December 2026; the terms of his departure are yet to be set in a written agreement.
Read the filing on SEC.gov ↗
Oct 29, 8:16 AM ET
Alnylam reported third quarter 2026 total revenues of $1.46 billion, up 17% from a year earlier, led by net product revenues of $1.29 billion, up 52%. GAAP net income reached $2.17 billion, or $15.72 per diluted share, but that figure includes a $1.9 billion income tax benefit, while GAAP income from operations fell 6% to $345.8 million. The company reiterated its full-year 2026 guidance.
- Total revenues were $1,458.1 million versus $1,249.0 million in Q3 2025, up 17%.
- Total net product revenues were $1,292 million, up 52%, with Total TTR net product revenues at $1,150 million.
- GAAP income from operations was $345.8 million, down 6% from $368.0 million, while GAAP diluted EPS was $15.72 versus $2.14, helped by a $1.9 billion tax benefit.
- Full-year 2026 total net product revenues guidance of $4,700 million to $5,100 million was reiterated.
Read the filing on SEC.gov ↗
Jul 30, 8:06 AM ET
Alnylam reported second-quarter 2026 total revenues of $1.29 billion, up 67% from a year earlier, and GAAP net income of $164 million, compared with a net loss of $72 million in the prior-year quarter. The company lowered its full-year 2026 TTR net product revenue guidance to $4.2 billion to $4.5 billion from $4.4 billion to $4.7 billion, citing normalizing second-line demand for AMVUTTRA in the U.S.
- Q2 2026 total revenues were $1,290.9 million, up 67% from $773.7 million in Q2 2025.
- GAAP net income was $164.5 million, or $1.21 per diluted share, versus a loss of $0.55 per share a year earlier.
- Full-year 2026 TTR net product revenue guidance was cut to $4,200 million to $4,500 million from $4,400 million to $4,700 million.
- Full-year 2026 collaboration and royalty revenue guidance was raised to $575 million to $625 million from $400 million to $500 million.
Read the filing on SEC.gov ↗
May 27, 4:30 PM ET
Effective June 1, 2026, Alnylam expanded its board from ten to eleven members and elected Benjamin F. Cravatt, Ph.D. to fill the new seat. At its annual meeting, stockholders re-elected three Class I directors and approved executive pay in a non-binding vote, though one director's support was notably lower than the others.
- Dr. Cravatt receives a $75,000 annual cash retainer and a stock option with a $600,000 grant date fair value.
- Stuart A. Arbuckle, Yvonne L. Greenstreet, M.D., and Elliott Sigal, M.D., Ph.D. were re-elected as Class I directors to serve until the 2029 annual meeting.
- Stockholders approved executive compensation with 111,772,389 votes for and 8,552,534 against.
- PricewaterhouseCoopers LLP was ratified as independent auditor for fiscal 2026 with 119,847,735 votes for.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.